|
1
|
Ljungberg B, Albiges L, Abu-Ghanem Y,
Bedke J, Capitanio U, Dabestani S, Fernández-Pello S, Giles RH,
Hofmann F, Hora M, et al: European association of urology
guidelines on renal cell carcinoma: The 2022 update. Eur Urol.
82:399–410. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang W, Liu R, Zhang L, Wang C, Dong Z,
Feng J, Luo M, Zhang Y, Xu Z, Lv S and Wei Q: Downregulation of
miR-335 exhibited an oncogenic effect via promoting KDM3A/YAP1
networks in clear cell renal cell carcinoma. Cancer Gene Ther.
29:573–584. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Choueiri TK and Motzer RJ: Systemic
therapy for metastatic renal-cell carcinoma. N Engl J Med.
376:354–366. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lin E, Liu X, Liu Y, Zhang Z, Xie L, Tian
K, Liu J and Yu Y: Roles of the dynamic tumor immune
microenvironment in the individualized treatment of advanced clear
cell renal cell carcinoma. Front Immunol. 12:6533582021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li F, Feng Y, Jiang Q, Zhang J, Wu F, Li
Q, Jing X, Wang X and Huang C: Pan-cancer analysis, cell and animal
experiments revealing TEAD4 as a tumor promoter in ccRCC. Life Sci.
293:1203272022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ren X, Diao X, Zhuang J and Wu D:
Structural basis for the allosteric inhibition of hypoxia-inducible
factor (HIF)-2 by belzutifan. Mol Pharmacol. Sep 27–2022.doi:
10.1124/molpharm.122.000525 (Epub ahead of print). View Article : Google Scholar
|
|
7
|
Budka JA, Ferris MW, Capone MJ and
Hollenhorst PC: Common ELF1 deletion in prostate cancer bolsters
oncogenic ETS function, inhibits senescence and promotes docetaxel
resistance. Genes Cancer. 9:198–214. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Honda S, Kobayashi T, Kajino K, Urakami S,
Igawa M and Hino O: Ets protein Elf-1 bidirectionally suppresses
transcriptional activities of the tumor suppressor Tsc2 gene and
the repair-related Nth1 gene. Mol Carcinogenesis. 37:122–129. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li B, Yao B, Guo X, Wang Z, Xie W, Wu X,
Wang F and Mei Y: c-Myc-induced long noncoding RNA MIRE cooperates
with hnRNPK to stabilize ELF2 mRNA and promotes clear cell renal
cell carcinogenesis. Cancer Gene Ther. May 29–2023.doi:
10.1038/s41417-023-00631-0 (Epub ahead of print). View Article : Google Scholar
|
|
10
|
Xiao XH and He SY: ELF1 activated long
non-coding RNA CASC2 inhibits cisplatin resistance of non-small
cell lung cancer via the miR-18a/IRF-2 signaling pathway. Eur Rev
Med Pharmacol Sci. 24:3130–3142. 2020.PubMed/NCBI
|
|
11
|
Brunner M, Mullen L, Jauk F, Oliver J,
Cayol F, Minata J, Herrera V, Pavicic W, Luna D, Risk M, et al:
Automatic integration of clinical and genetic data using
cBioPortal. Stud Health Technol Inform. 290:799–803.
2022.PubMed/NCBI
|
|
12
|
Chen X, Chen J, Feng W, Huang W, Wang G,
Sun M, Luo X, Wang Y, Nie Y, Fan D, et al: FGF19-mediated ELF4
overexpression promotes colorectal cancer metastasis through
transactivating FGFR4 and SRC. Theranostics. 13:1401–1418. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hu Y, Yan Y, Xu Y, Yang H, Fang L, Liu Y,
Li X, Li Q and Yan H: Expression and clinical significance of WWOX,
Elf5, Snail1 and EMT related factors in epithelial ovarian cancer.
Oncol Lett. 19:1281–1290. 2020.PubMed/NCBI
|
|
14
|
Kulkarni DP, Wadia PP, Pradhan TN, Pathak
AK and Chiplunkar SV: Mechanisms involved in the down-regulation of
TCR zeta chain in tumor versus peripheral blood of oral cancer
patients. Int J Cancer. 124:1605–1613. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gallego-Ortega D, Ledger A, Roden DL, Law
AM, Magenau A, Kikhtyak Z, Cho C, Allerdice SL, Lee HJ, Valdes-Mora
F, et al: ELF5 drives lung metastasis in luminal breast cancer
through recruitment of Gr1+ CD11b+ myeloid-derived suppressor
cells. PLoS Biol. 13:e10023302015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tang Z, Kang B, Li C, Chen T and Zhang Z:
GEPIA2: An enhanced web server for large-scale expression profiling
and interactive analysis. Nucleic Acids Res. 47:W556–W560. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
von Roemeling CA, Radisky DC, Marlow LA,
Cooper SJ, Grebe SK, Anastasiadis PZ, Tun HW and Copland JA:
Neuronal pentraxin 2 supports clear cell renal cell carcinoma by
activating the AMPA-selective glutamate receptor-4. Cancer Res.
74:4796–4810. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Robinson MD, McCarthy DJ and Smyth GK:
edgeR: A Bioconductor package for differential expression analysis
of digital gene expression data. Bioinformatics. 26:139–140. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and
Varambally S: UALCAN: A portal for facilitating tumor subgroup gene
expression and survival analyses. Neoplasia. 19:649–658. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rhodes DR, Yu J, Shanker K, Deshpande N,
Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM:
ONCOMINE: A cancer microarray database and integrated data-mining
platform. Neoplasia. 6:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vasaikar SV, Straub P, Wang J and Zhang B:
LinkedOmics: Analyzing multi-omics data within and across 32 cancer
types. Nucleic Acids Res. 46:D956–D963. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li T, Fan J, Wang B, Traugh N, Chen Q, Liu
JS, Li B and Liu XS: TIMER: A web server for comprehensive analysis
of tumor-infiltrating immune cells. Cancer Res. 77:e108–e110. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Malekghasemi S, Majidi J, Baradaran B and
Aghebati-Maleki L: Prostate cancer cells modulate the
differentiation of THP-1 cells in response to etoposide and TLR
agonists treatments. Cell Biol Int. 44:2031–2041. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu L, Cui J, Zhao Y, Liu X, Chen L, Xia
Y, Wang Y, Chen S, Sun S, Shi B and Zou Y: KDM6A-ARHGDIB axis
blocks metastasis of bladder cancer by inhibiting Rac1. Mol Cancer.
20:772021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ye J, Chen X and Lu W: Identification and
experimental validation of immune-associate lncRNAs for predicting
prognosis in cervical cancer. Onco Targets Ther. 14:4721–4734.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Guo X, Li H, Zhang M and Li R: LncRNA GAS6
antisense RNA 1 facilitates the tumorigenesis of clear cell renal
cell carcinoma by regulating the AMP-activated protein kinase/mTOR
signaling pathway. Oncol Lett. 22:7272021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Galang CK, Muller WJ, Foos G, Oshima RG
and Hauser CA: Changes in the expression of many Ets family
transcription factors and of potential target genes in normal
mammary tissue and tumors. J Biol Chem. 279:11281–11292. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Enfield KSS, Marshall EA, Anderson C, Ng
KW, Rahmati S, Xu Z, Fuller M, Milne K, Lu D, Shi R, et al:
Epithelial tumor suppressor ELF3 is a lineage-specific amplified
oncogene in lung adenocarcinoma. Nat Commun. 10:54382019.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Miyano M, Sayaman RW, Shalabi SF, Senapati
P, Lopez JC, Angarola BL, Hinz S, Zirbes A, Anczukow O, Yee LD, et
al: Breast-specific molecular clocks comprised of ELF5 expression
and promoter methylation identify individuals susceptible to cancer
initiation. Cancer Prev Res (Phila). 14:779–794. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wu B, Cao X, Liang X, Zhang X, Zhang W,
Sun G and Wang D: Epigenetic regulation of Elf5 is associated with
epithelial-mesenchymal transition in urothelial cancer. PLoS One.
10:e01175102015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Goncharova IA, Zarubin AA, Babushkina NP,
Koroleva IA and Nazarenko MS: Changes in DNA methylation profile in
liver tissue during progression of HCV-induced fibrosis to
hepatocellular carcinoma. Vavilovskii Zhurnal Genet Selektsii.
27:72–82. 2023.PubMed/NCBI
|
|
33
|
Du H, Xia H, Liu T, Li Y, Liu J, Xie B,
Chen J, Liu T, Cao L, Liu S, et al: Suppression of ELF4 in
ulcerative colitis predisposes host to colorectal cancer. iScience.
24:1021692021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang Y, Zuo M, Jin H, Lai M, Luo J and
Cheng Z: Inhibition of ELF3 confers synthetic lethality of PARP
inhibitor in non-small cell lung cancer. J Recept Signal Transduct
Res. 41:304–311. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Guo Y, Ma D, Jia SF, Liu J, Fan SB, Zhang
M, Shi LR, Jiang LL, Shi JX, Wang HQ, et al: Proliferation of
MicroRNA-365 and E74-like factor 4 in cervical cancer cells and its
clinical significance. Zhongguo Yi Xue Ke Xue Yuan Xue Bao.
41:220–227. 2019.(In Chinese). PubMed/NCBI
|
|
36
|
Kafita D, Daka V, Nkhoma P, Zulu M, Zulu
E, Tembo R, Ngwira Z, Mwaba F, Sinkala M and Munsaka S: High ELF4
expression in human cancers is associated with worse disease
outcomes and increased resistance to anticancer drugs. PloS one.
16:e02489842021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yang L, Wang H, Guo M, He M, Zhang W, Zhan
M and Liu Y: ELF3 promotes gemcitabine resistance through
PKMYT1/CDK1 signaling pathway in gallbladder cancer. Cell Oncol
(Dordr). Mar 29–2023.doi: 10.1007/s13402-023-00799-5 (Epub ahead of
print). View Article : Google Scholar
|
|
38
|
Endo A, Tomizawa D, Aoki Y, Morio T,
Mizutani S and Takagi M: EWSR1/ELF5 induces acute myeloid leukemia
by inhibiting p53/p21 pathway. Cancer Sci. 107:1745–1754. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kosti A, Chiou J, Guardia GDA, Lei X,
Balinda H, Landry T, Lu X, Qiao M, Gilbert A, Brenner A, et al:
ELF4 is a critical component of a miRNA-transcription factor
network and is a bridge regulator of glioblastoma receptor
signaling and lipid dynamics. Neuro Oncol. 25:459–470. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Suico MA, Shuto T and Kai H: Roles and
regulations of the ETS transcription factor ELF4/MEF. J Mol Cell
Biol. 9:168–177. 2017.PubMed/NCBI
|
|
41
|
Jin H, Liu W, Xu W, Zhou L, Luo H, Xu C,
Chen X and Chen W: Identification of prognostic factors in
cholangiocarcinoma based on integrated ceRNA network analysis.
Comput Math Methods Med. 2022:71027362022. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kosti A, Du L, Shivram H, Qiao M, Burns S,
Garcia JG, Pertsemlidis A, Iyer VR, Kokovay E and Penalva LOF: ELF4
is a target of miR-124 and promotes neuroblastoma proliferation and
undifferentiated state. Mol Cancer Res. 18:68–78. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang WL, Hong GC, Chien PJ, Huang YH, Lee
HT, Wang PH, Lee YC and Chang WW: Tribbles pseudokinase 3
contributes to cancer stemness of endometrial cancer cells by
regulating β-catenin expression. Cancers. 12:37852020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gao J, Ao YQ, Zhang LX, Deng J, Wang S,
Wang HK, Jiang JH and Ding JY: Exosomal circZNF451 restrains
anti-PD1 treatment in lung adenocarcinoma via polarizing
macrophages by complexing with TRIM56 and FXR1. J Exp Clin Cancer
Res. 41:2952022. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yao JJ, Liu Y, Lacorazza HD, Soslow RA,
Scandura JM, Nimer SD and Hedvat CV: Tumor promoting properties of
the ETS protein MEF in ovarian cancer. Oncogene. 26:4032–4037.
2007. View Article : Google Scholar : PubMed/NCBI
|
